Solvay Pharma India Ltd.[Amalgamated] - Research Center
532447 DUPHARPH Group (N.A.) BSE data
Results
Statement
More
Dec ' 10 |
Dec ' 09 |
Dec ' 08 |
Dec ' 07 |
Dec ' 06 |
Equity share capital
Share application money
Preference share capital
Reserves & surplus
160.88 |
125.04 |
104.22 |
81.75 |
77.01 |
Secured loans
Unsecured loans
Total
165.93 |
130.09 |
109.27 |
86.80 |
82.10 |
Gross block
62.43 |
64.23 |
27.83 |
8.20 |
10.24 |
Less : revaluation reserve
Less : accumulated depreciation
26.77 |
26.69 |
25.37 |
3.79 |
3.15 |
Net block
35.66 |
37.54 |
2.46 |
4.41 |
7.09 |
Capital work-in-progress
Investments
36.67 |
15.93 |
16.66 |
39.84 |
14.02 |
Current assets, loans & advances
148.75 |
118.25 |
102.89 |
74.45 |
86.69 |
Less : current liabilities & provisions
55.15 |
41.63 |
47.90 |
31.96 |
25.80 |
Total net current assets
93.60 |
76.62 |
54.99 |
42.49 |
60.89 |
Miscellaneous expenses not written
Total
165.93 |
130.09 |
109.27 |
86.80 |
82.10 |
Book value of unquoted investments
36.67 |
15.93 |
16.66 |
39.84 |
14.02 |
Market value of quoted investments
Contingent liabilities
Number of equity sharesoutstanding (Lacs)
50.50 |
50.50 |
50.50 |
50.50 |
50.50 |